样式: 排序: IF: - GO 导出 标记为已读
-
A critical review of the dextroamphetamine transdermal system for the treatment of ADHD in adults and pediatric patients Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-03-14 Ann Childress, Nicolas Vaughn
The dextroamphetamine transdermal system (d-ATS) is a stimulant patch recently approved by the United States (U.S.) Food and Drug Administration for the treatment of attention-deficit/hyperactivity...
-
Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-03-06 Giovanna Cirnigliaro, Vera Battini, Michele Castiglioni, Marica Renne, Giulia Mosini, Stefania Cheli, Carla Carnovale, Bernardo Dell’Osso
Paliperidone Palmitate is the only antipsychotic that has been developed in three different intramuscular long-acting injectable (LAI) dosing regimen: monthly (PP1M), quarterly (PP3M), and from 202...
-
The latest advances in the pharmacological management of focal epilepsies in children: a narrative review Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-03-05 Sara Matricardi, Giovanna Scorrano, Giovanni Prezioso, Beatrice Burchiani, Giuseppe Di Cara, Pasquale Striano, Francesco Chiarelli, Alberto Verrotti
Focal epilepsy constitutes the most common epilepsy in children, and medical treatment represents the first-line therapy in this condition. The main goal of medical treatment for children and adole...
-
Diagnosing epileptic seizures in patients with Alzheimer’s disease and deciding on the appropriate treatment plan Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-03-01 Francesco Brigo, Simona Lattanzi
Alzheimer’s disease (AD) is the predominant cause of dementia and a significant contributor to morbidity among the elderly. Patients diagnosed with AD face an increased risk of epileptic seizures.H...
-
Pharmacological management of gambling disorder: an update of the literature Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-03-01 Gemma Mestre-Bach, Marc N. Potenza
Gambling disorder (GD) is a mental health condition characterized by persistent and problematic betting behavior. GD generates distress and impairment, and treatment options include psychological a...
-
Diagnosis of Lennox-Gastaut syndrome and strategies for early recognition Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-02-28 Suresh Pujar, J Helen Cross
Lennox Gastaut syndrome (LGS) as an electroclinical diagnosis has been utilized as a clinical entity for more than 70 years. However, with the recognition of other distinct electroclinical epilepsy...
-
The management of neurofibromatosis type 1 (NF1) in children and adolescents Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-02-27 Nino Kerashvili, David H. Gutmann
Neurofibromatosis type 1 (NF1) is a rare neurogenetic disorder characterized by multiple organ system involvement and a predisposition to benign and malignant tumor development. With revised NF1 cl...
-
The impact of exercise on Alzheimer’s disease progression Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-02-23 Thierry Paillard, Hubert Blain, Pierre Louis Bernard
The preventive effects of chronic physical exercise (CPE) on Alzheimer’s disease (AD) are now admitted by the scientific community. Curative effects of CPE are more disputed, but they deserve to be...
-
A review of amphetamine extended release once-daily options for the management of attention-deficit hyperactivity disorder Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-02-23 Kendall Abbas, Elizabeth W. Barnhardt, Patricia L. Nash, Maria Streng, Daniel L. Coury
Amphetamine preparations are one of the two categories of stimulant medications approved for the treatment of attention deficit hyperactivity disorder (ADHD). Optimal treatment of ADHD aims to redu...
-
An analysis of omega-3 clinical trials and a call for personalized supplementation for dementia prevention Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-02-20 Nicolás Castellanos-Perilla, Miguel Germán Borda, Dag Aarsland, George E. Barreto
Targeted interventions are needed to delay or prevent the onset of neurodegenerative diseases. Poor dietary habits are associated with cognitive decline, highlighting the benefits of a healthy diet...
-
Treatment of dissociative identity disorder: leveraging neurobiology to optimize success Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-02-15 Juliann B. Purcell, Bethany Brand, Heidi A. Browne, Richard A. Chefetz, Meghan Shanahan, Zoe A. Bair, Kim A. Baranowski, Vona Davis, Patricia Mangones, Rebecca L. Modell, Cori A. Palermo, Emma C. Robertson, Matthew A. Robinson, Laura Ward, Sherry Winternitz, Milissa L. Kaufman, Lauren A. M. Lebois
Dissociative identity disorder (DID) is a treatable mental health condition that is associated with a range of psychobiological manifestations. However, historical controversy, modern day misunders...
-
What impact can brain stimulation interventions have on borderline personality disorder? Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-02-13 Jacopo Lisoni, Gabriele Nibbio, Giulia Baldacci, Andrea Cicale, Andrea Zucchetti, Lorenzo Bertoni, Irene Calzavara Pinton, Nicola Necchini, Giacomo Deste, Stefano Barlati, Antonio Vita
Borderline personality disorder (BPD) is a severe mental disorder characterized by emotion dysregulation, impulsivity, neuropsychological impairment, and interpersonal instability, presenting with ...
-
The promise and challenges of transcranial magnetic stimulation and deep brain stimulation as therapeutic options for obsessive-compulsive disorder Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-02-06 Nicola Acevedo, David Castle, Susan Rossell
Obsessive compulsive disorder (OCD) represents a complex and often difficult to treat disorder. Pharmacological and psychotherapeutic interventions are often associated with sub-optimal outcomes, a...
-
Careful considerations for the treatment of posttraumatic stress disorder during and following pregnancy Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-02-06 Casey Oliver, Erika Puiras, Verinder Sharma, Dwight Mazmanian
The focus on perinatal mental health has expanded recently, though there is less research on post-traumatic stress disorder (PTSD). Therefore, a review of the literature was undertaken and coupled ...
-
An update on the pharmacotherapeutic options for complex regional pain syndrome Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-02-06 Giovanni Iolascon, Francesco Snichelotto, Antimo Moretti
Complex regional pain syndrome (CRPS) is a rare and painful condition that has a wide range of triggering factors, often traumatic, and can present various clinical manifestations. The lack of know...
-
Postoperative analgesic options after spine surgery: finding the optimal treatment strategies Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-02-06 Alina Razak, Benjamin Corman, John Servider, Ana Mavarez-Martinez, Zhaosheng Jin, Harry Mushlin, Sergio D. Bergese
Spine surgery is one of the most common types of surgeries performed in the United States; however, managing postoperative pain following spine surgery has proven to be challenging. Patients with s...
-
An update on the role of magnetic resonance imaging in predicting and monitoring multiple sclerosis progression Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-02-06 Piriyankan Ananthavarathan, Nitin Sahi, Declan T Chard
While magnetic resonance imaging (MRI) is established in diagnosing and monitoring disease activity in multiple sclerosis (MS), its utility in predicting and monitoring disease progression is less ...
-
Emerging antibody-based therapies for Huntington’s disease: current status and perspectives for future development Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-02-07 Anamaria Jurcau, Aurel Simion, Maria Carolina Jurcau
Being an inherited neurodegenerative disease with an identifiable genetic defect, Huntington’s disease (HD) is a suitable candidate for early intervention, possibly even in the pre-symptomatic stag...
-
Are pharmacotherapeutics effective for treating aphasia? Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-02-07 Guadalupe Dávila, Marcelo L. Berthier
Aphasia is a communication disorder resulting from stroke and/or neurodegenerative conditions which involve the left cerebral hemisphere. It is a debilitating disorder affecting a person’s ability ...
-
Evaluating fenfluramine hydrochloride as an oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-02-07 Frank M. C. Besag, Michael J. Vasey, Richard F. M. Chin
Lennox-Gastaut syndrome (LGS) is a severe childhood-onset developmental and epileptic encephalopathy characterized by treatment-refractory seizures, including tonic/atonic ‘drop’ seizures, and inte...
-
Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-02-05 Ludovic Samalin, Ludivine Boudieu, Pierre Michel Llorca
An aripiprazole long-acting injectable (LAI) antipsychotic is now available for gluteal administration every 2 months via two different formulations: aripiprazole lauroxil (AL) and aripiprazole mon...
-
Beyond pain catastrophizing: rationale and recommendations for targeting trauma in the assessment and treatment of chronic pain Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-01-30 Jolin B. Yamin, Samantha M. Meints, Robert R. Edwards
Published in Expert Review of Neurotherapeutics (Vol. 24, No. 3, 2024)
-
Omaveloxolone for the treatment of Friedreich ataxia: clinical trial results and practical considerations Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-01-30 David R Lynch, Susan Perlman, Kim Schadt
Omavaloxolone, an NRF2 activator, recently became the first drug approved specifically for the treatment of Friedreich ataxia (FRDA). This landmark achievement provides a background for a review of...
-
The latest developments with internet-based psychological treatments for depression Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-01-26 Gerhard Andersson
Internet-based psychological treatments for depression have been around for more than 20 years. There has been a continuous line of research with new research questions being asked and studies cond...
-
Family accommodation: a diagnostic feature of obsessive-compulsive disorder? Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-01-26 Rebecca G. Etkin, Michael H. Bloch, Eli R. Lebowitz
Published in Expert Review of Neurotherapeutics (Vol. 24, No. 2, 2024)
-
Evaluating avalglucosidase alfa for the management of late-onset Pompe disease Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-01-23 Corrado Angelini
Glycogenosis type II (GSDII) is a rare autosomal disorder that is caused by the deficiency of alpha-glucosidase, a lysosomal enzyme that hydrolyzes glycogen to glucose. Autophagy dysregulation play...
-
A proposal for a shared therapeutic algorithm in children with prolonged convulsive seizures and status epilepticus Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-01-17 Roberta Roberti, Antonella Riva, Gianluca D’Onofrio, Emanuele Giacheri, Elisabetta Amadori, Maria Stella Vari, Angela La Neve, Federico Vigevano, Alberto Verrotti, Duccio Maria Cordelli, Antonino Romeo, Antonella Palmieri, Maria Margherita Mancardi, Sergio Caglieris, Antonio Varone, Carlo Minetti, Emilio Russo, Silvia Buratti, Pasquale Striano
Published in Expert Review of Neurotherapeutics (Vol. 24, No. 2, 2024)
-
Correction Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-01-08
Published in Expert Review of Neurotherapeutics (Vol. 24, No. 1, 2024)
-
An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why? Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-01-08 Mainak Bardhan, Debankur Dey, Vinay Suresh, Binish Javed, Vyshak Alva Venur, Neha Joe, Ritvika Kalidindi, Ahmad Ozair, Marium Khan, Reshma Mahtani, Simon Lo, Yazmin Odia, Manmeet S. Ahluwalia
Neoplastic meningitis (NM), also known as leptomeningeal carcinomatosis, is characterized by the infiltration of tumor cells into the meninges, and poses a significant therapeutic challenge owing t...
-
Accelerating the development of noninvasive brain stimulation devices: using design thinking to facilitate its clinical use and acceptance Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-01-08 Kevin Pacheco-Barrios, Anna Carolyna Gianlorenco, Lucas Camargo, Mustafa Reha Dodurgali, Anamon Tangjade, Felipe Fregni
Published in Expert Review of Neurotherapeutics (Vol. 24, No. 1, 2024)
-
The early recognition and diagnosis of neoplastic meningitis Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-01-08 Alessia Pellerino, Luca Bertero, Edoardo Pronello, Roberta Rudà, Riccardo Soffietti
The diagnosis and monitoring of leptomeningeal metastases (LM) from solid tumors are challenging, and the combination of neurological symptoms, MRI findings, and cerebrospinal fluid (CSF) cytology ...
-
Considerations for hormonal therapy in migraine patients: a critical review of current practice Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-01-08 Romy van Lohuizen, Jakob Paungarttner, Christian Lampl, Antoinette MaassenVanDenBrink, Linda Al-Hassany
Migraine, a neurovascular headache disorder, is a leading cause of disability worldwide. Within the multifaceted pathophysiology of migraine, hormonal fluctuations play an evident triggering and ex...
-
Does electrical stimulation still have a place in the treatment armamentarium for Bell’s palsy? Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-01-08 Myriam Loyo Li, Michelle H. Cameron, Gerd Fabian Volk
Published in Expert Review of Neurotherapeutics (Vol. 24, No. 1, 2024)
-
Current challenges in primary lateral sclerosis diagnosis Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-01-08 Miguel Oliveira Santos, Michael Swash, Mamede de Carvalho
Primary lateral sclerosis (PLS) is a rare, adult-onset and slowly progressive motor neuron disorder whose clinical core is characterized by upper motor neuron (UMN) dysfunction. Its formal diagnosi...
-
Efficacy analysis of three brain stimulation techniques for Alzheimer’s disease: a meta-analysis of repeated transcranial magnetic stimulation, transcranial direct current stimulation, and deep brain stimulation Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-01-08 Peilin Huang, Lin Lin, Jiejun Zhang, Yingzhe Cheng, Xiaodong Pan
This systematic review and meta-analysis study investigates the efficacy of repeated transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), and deep brain stimula...
-
Current perspectives on tractography-guided deep brain stimulation for the treatment of mood disorders Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-01-08 Jason L. Chan, Ariane V. Carpentier, Erik H. Middlebrooks, Michael S. Okun, Joshua K. Wong
Deep brain stimulation (DBS) is an emerging therapy for mood disorders, particularly treatment-resistant depression (TRD). Different brain areas implicated in depression-related brain networks have...
-
Current perspectives on prevention of vascular cognitive impairment and promotion of vascular brain health Expert Rev. Neurother. (IF 4.3) Pub Date : 2024-01-08 Raj N Kalaria, Rufus O Akinyemi, Stella-Maria Paddick, Masafumi Ihara
The true global burden of vascular cognitive impairment (VCI) is unknown. Reducing risk factors for stroke and cardiovascular disease would inevitably curtail VCI.The authors review current diagnos...
-
An overview of the utility of prasugrel hydrochloride as a treatment option for ischemic stroke Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-30 Udaya S Tantry, Sahib Singh, Kevin P Bliden, Paul A Gurbel, William Ashley
Prasugrel, a potent P2Y12 receptor inhibitor, is not currently recommended in patients with stroke due to a higher rate of recurrent stroke. Prasugrel was associated with comparable efficacy to clo...
-
Is internet-based psychological therapy effective for treating major depressive disorder? Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-19 Daniel Fatori, Ives C Passos, André R Brunoni
Published in Expert Review of Neurotherapeutics (Vol. 24, No. 3, 2024)
-
Long-term outcomes in refractory status epilepticus Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Branislava Raičević, Snežana Janković, Refet Gojak, Vera Dabanović, Slobodan Janković
Refractory status epilepticus (RSE) is a diagnosis that can be made when tonic-clonic status epilepticus (SE) and focal SE cannot be stopped by at least two anti-seizure medications after 30 and 60...
-
An update on combination therapies for multiple sclerosis: where are we now? Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Per Soelberg Sorensen, Melinda Magyari, Finn Sellebjerg
In theory, combination of two agents, which are suboptimal when given individually, may result in a significant increase in therapeutic effect. Combination therapies have proven particularly effect...
-
What are the considerations when initiating treatment for epilepsy in children? Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Francesco Pisani, Carlotta Spagnoli
There is a very wide spectrum of epilepsies and developmental and epileptic encephalopathies that affect children, from self-limited forms, not necessarily requiring treatment, to severe drug-resis...
-
Treatment of septic encephalopathy and encephalitis – a critical appraisal Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Simone C. Tauber, Roland Nau
The central nervous system is frequently involved during severe sepsis. Patients either develop septic encephalopathy characterized by delirium and coma or focal neurological signs as a consequence...
-
Virtual reality technology in the treatment of anxiety – progress and future challenges Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Richard J Porter, Ben Beaglehole, Nilufar Baghaei
Published in Expert Review of Neurotherapeutics (Vol. 23, No. 12, 2023)
-
Identifying risk factors for chronic postsurgical pain and preventive measures: a comprehensive update Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Joseph V. Pergolizzi Jr, Jo Ann LeQuang, Peter Magnusson, Giustino Varrassi
Chronic postsurgical pain (CPSP) is a prevalent condition that can diminish health-related quality of life, cause functional deficits, and lead to patient distress. Rates of CPSP are higher for cer...
-
From theory to practice: what is the potential of artificial intelligence in the future of neurosurgery? Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Hannah Planells, Viraj Parmar, Hani J Marcus, Anand S Pandit
Published in Expert Review of Neurotherapeutics (Vol. 23, No. 12, 2023)
-
Advances in amyloid-targeting monoclonal antibodies for Alzheimer’s disease: clinical and public health issues Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Simone Salemme, Antonio Ancidoni, Nicoletta Locuratolo, Paola Piscopo, Eleonora Lacorte, Marco Canevelli, Nicola Vanacore
Alzheimer’s disease (AD) is a major global public health challenge. To date, no treatments have been shown to stop the underlying pathological processes. The cerebral accumulation of amyloid-beta (...
-
Advances in molecular and imaging biomarkers in lower-grade gliomas Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Alberto Picca, Francesco Bruno, Lucia Nichelli, Marc Sanson, Roberta Rudà
Lower-grade (grade 2–3) gliomas (LGGs) constitutes a group of primary brain tumors with variable clinical behaviors and treatment responses. Recent advancements in molecular biology have redefined ...
-
Managing antipsychotic-related sexual dysfunction in patients with schizophrenia Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Carlos Silva, Marta Rebelo, Inês Chendo
Schizophrenia is a psychotic disorder and one of the most severe and impactful mental illnesses. Sexual dysfunction is highly prevalent in patients with schizophrenia but remains underdiagnosed and...
-
Tackling seizures in patients with Alzheimer’s disease Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Mario Tombini, Marilisa Boscarino, Vincenzo Di Lazzaro
In past years, a possible bidirectional link between epilepsy and Alzheimer’s disease (AD) has been proposed: if AD patients are more likely to develop epilepsy, people with late-onset epilepsy evi...
-
Advances in the treatment of human T-cell lymphotropic virus type-I associated myelopathy Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Baratali Mashkani, Mohammad Jalili Nik, Seyed Abdolrahim Rezaee, Reza Boostani
Nearly 2–3% of those 10 to 20 million individuals infected with the Human T-cell lymphotropic virus type-1 (HTLV-1); are predisposed to developing HTLV-1-associated myelopathy/tropical spastic para...
-
Obtaining long-term recovery: advances in optimizing treatment outcomes in patients with binge-eating disorder Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Carlos Eduardo Ferreira de Moraes, Brooke Donnelly, Jose Carlos Appolinario, Phillipa Hay
Binge-eating disorder (BED) is a complex and disabling eating disorder (ED) associated with considerable burden and impairments in quality of life and physical/mental health. It has been recognized...
-
Emerging biomarkers to predict clinical outcomes in Guillain–Barré syndrome Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Gautier Breville, Egle Sukockiene, Maria Isabel Vargas, Agustina M. Lascano
Guillain–Barré syndrome (GBS) is an immune-mediated poly(radiculo)neuropathy with a variable clinical outcome. Identifying patients who are at risk of suffering from long-term disabilities is a gre...
-
Imaging of congenital and developmental cystic lesions of the brain: a narrative review Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Eliza T. Firn, Hector H. Garcia, Otto Rapalino, Anna M. Cervantes-Arslanian
Congenital and developmental intracranial cysts represent a large heterogenous group with varied presentations and etiologies. They can range from normal variants to pathologic lesions often associ...
-
Illuminating the way: the role of bright light therapy in the treatment of depression Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Biljana Kosanovic Rajacic, Marina Sagud, Nela Pivac, Drazen Begic
Despite the growing number of different therapeutic options, treatment of depression is still a challenge. A broader perspective reveals the benefits of bright light therapy (BLT). It stimulates in...
-
Contemporary diagnosis and treatment of conduct disorder in youth Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Gabriele Masi, Sara Carucci, Pietro Muratori, Carla Balia, Gianluca Sesso, Annarita Milone
Conduct disorder (CD) is characterized by repetitive and persistent antisocial behaviors, being among the most frequently reported reasons of referral in youth. CD is a highly heterogeneous disorde...
-
Current and emerging targeted therapies for spinal muscular atrophy Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Yuliya Lakhina, Nicholas M. Boulis, Anthony Donsante
Spinal muscular atrophy (SMA) is a progressive neurodegenerative disorder caused by insufficiency or total absence of the survival motor neuron protein due to a mutation in the SMN1 gene. The copy ...
-
How does “Pure-O” obsessive-compulsive disorder impact on a patient’s treatment plan? Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Giacomo Grassi
Published in Expert Review of Neurotherapeutics (Vol. 23, No. 12, 2023)
-
Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Dejan Jakimovski, Bianca Weinstock-Guttman, Robert Zivadinov
B cell depletion has been established as an efficacious anti-inflammatory therapy in people with relapsing forms of multiple sclerosis (MS). Ublituximab (ublituximab-xiiy) is the latest approved ch...
-
Tackling the neurological manifestations in Wilson’s disease – currently available treatment options Expert Rev. Neurother. (IF 4.3) Pub Date : 2023-12-15 Tomasz Litwin, Petr Dusek, Agnieszka Antos, Anna Członkowska, Jan Bembenek
Wilson’s disease (WD) is a potentially treatable, inherited disorder resulting from impaired copper metabolism. Pathological copper accumulation causes a range of symptoms, most commonly hepatic an...